Zacks Research Analysts Increase Earnings Estimates for Denali Therapeutics Inc. (NASDAQ:DNLI)

Denali Therapeutics Inc. (NASDAQ:DNLI) – Zacks Research boosted their Q2 2024 EPS estimates for Denali Therapeutics in a report released on Thursday, May 23rd. Zacks Research analyst A. Chakraborty now anticipates that the company will post earnings per share of ($0.72) for the quarter, up from their prior forecast of ($0.73). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.77) per share. Zacks Research also issued estimates for Denali Therapeutics’ Q3 2024 earnings at ($0.71) EPS, Q4 2024 earnings at ($0.74) EPS, FY2024 earnings at ($2.85) EPS, Q3 2025 earnings at ($0.72) EPS, Q4 2025 earnings at ($0.70) EPS, FY2025 earnings at ($2.83) EPS, Q1 2026 earnings at ($0.71) EPS and FY2026 earnings at ($2.79) EPS.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 11.46% and a negative net margin of 36.51%. During the same quarter in the prior year, the company earned ($0.80) earnings per share.

A number of other research analysts also recently issued reports on the stock. Wedbush reduced their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 8th. The Goldman Sachs Group cut their price objective on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. Stifel Nicolaus lowered their target price on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating for the company in a report on Wednesday, May 8th. HC Wainwright reissued a “buy” rating and issued a $95.00 price target on shares of Denali Therapeutics in a research note on Wednesday, May 8th. Finally, UBS Group reduced their price target on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, April 9th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.22.

Denali Therapeutics Stock Down 0.3 %

Shares of DNLI stock opened at $19.21 on Monday. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -20.01 and a beta of 1.39. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $33.31. The stock has a 50-day moving average price of $18.58 and a 200 day moving average price of $18.85.

Insider Buying and Selling

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of the business’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $18.29, for a total value of $30,471.14. Following the completion of the transaction, the director now directly owns 118,043 shares of the company’s stock, valued at $2,159,006.47. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Steve E. Krognes sold 92,500 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the completion of the sale, the director now owns 47,341 shares of the company’s stock, valued at $970,490.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 1,666 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $18.29, for a total transaction of $30,471.14. Following the completion of the sale, the director now directly owns 118,043 shares in the company, valued at $2,159,006.47. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Denali Therapeutics

A number of large investors have recently added to or reduced their stakes in DNLI. Bayesian Capital Management LP acquired a new position in shares of Denali Therapeutics during the first quarter worth about $447,000. Baker BROS. Advisors LP lifted its stake in Denali Therapeutics by 43.1% in the 1st quarter. Baker BROS. Advisors LP now owns 3,731,695 shares of the company’s stock valued at $76,574,000 after acquiring an additional 1,124,499 shares in the last quarter. Altitude Crest Partners Inc. acquired a new position in Denali Therapeutics during the 1st quarter worth approximately $4,301,000. Capital Research Global Investors boosted its position in Denali Therapeutics by 107.9% during the 1st quarter. Capital Research Global Investors now owns 6,049,957 shares of the company’s stock worth $124,145,000 after acquiring an additional 3,140,429 shares during the last quarter. Finally, EP Wealth Advisors LLC bought a new position in shares of Denali Therapeutics during the 1st quarter worth approximately $831,000. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.